Citi has reaffirmed its Buy rating on PI Industries stock, setting a target price of ₹4,400, implying a 39% upside from its current market price (CMP) of ₹3,160.00. The brokerage highlights growth in the agrichemical export business, new molecule commercialization, and expansion into the pharma CDMO segment as key drivers.
Key takeaways from Citi’s report:
- Agrichemical export business expected to deliver single-digit growth, supported by global demand recovery.
- Commercialized 25 new molecules in the last 3-4 years, strengthening its innovation pipeline.
- Global destocking cycle nearing completion, indicating potential demand recovery.
- Developing three new projects in the pharma CDMO segment, aiming for long-term revenue expansion.
Citi remains optimistic about PI Industries’ future prospects, citing robust product innovation, a diversified growth strategy, and a recovering export market as key catalysts for stock performance.
Disclaimer: This article is for informational purposes only and should not be considered financial advice. Investors should conduct their own research before making any investment decisions.